Stocks
NextCure, Inc.NXTC
NASDAQHealthcareBiotechnology$4.98
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing immunotherapies for cancer, with a focus on next-generation checkpoint inhibitors and myeloid cell modulators. Its lead candidate, NX-1607, is in early-stage trials for solid tumors, and investors track the stock for its pipeline progress and partnership potential.
52W Range: $1.55-$15.74
Congressional Interest in NextCure, Inc. (NXTC)
No congressional trades have been disclosed for NextCure, Inc. (NXTC) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading NXTC?
No congressional trades found for this stock.